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Abstract
Background: Antibodies are the main effector molecules in the defense against blood stages of
the malaria parasite Plasmodium falciparum. Understanding the mechanisms by which vaccine-
induced anti-blood stage antibodies work in protecting against malaria is essential for vaccine design
and testing.
Methods:  The effects of MSP-1p42-specific antibodies on the development of blood stage
parasites were studied using microscopy, flow cytometry and the pLDH assay. To determine allele-
specific effects, if present, allele-specific antibodies and the various parasite clones representative
of these alleles of MSP-1 were employed.
Results: The mode of action of anti-MSP-1p42 antibodies differs among the parasite clones tested:
anti-MSP-1p42 sera act mainly through invasion-inhibitory mechanisms against FVO parasites, by
either preventing schizonts from rupturing or agglutinating merozoites upon their release. The
same antibodies do not prevent the rupture of 3D7 schizonts; instead they agglutinate merozoites
and arrest the development of young parasites at the early trophozoite stage, thus acting through
both invasion- and growth inhibitory mechanisms. The second key finding is that antibodies have
access to the intra-erythrocytic parasite, as evidenced by the labeling of developing merozoites with
fluorochrome-conjugated anti-MSP-1p42 antibodies. Access to the parasite through this route
likely allows antibodies to exert their inhibitory activities on the maturing schizonts leading to their
inability to rupture and be released as infectious merozoites.
Conclusion: The identification of various modes of action by which anti-MSP-1 antibodies function
against the parasite during erythrocytic development emphasizes the importance of functional
assays for evaluating malaria vaccines and may also open new avenues for immunotherapy and
vaccine development.
Background
Natural immunity against malaria is based on the pres-
ence of antibodies directed against the blood stage para-
site, as demonstrated by passive transfer experiments of
immunoglobulins [1-3]. The mode of action of blood
stage-specific antibodies depends on their antigen-specif-
icity: they can bind to merozoites, opsonize and target
them towards phagocytic cells of the host [4], or prevent
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invasion of new erythrocytes [5]. Once infected, antibod-
ies against the asexual blood stage antigen Pf332 inhibit
the intra-erythrocytic development of Plasmodium falci-
parum [6-8]. Furthermore, antibodies against free parasitic
glycosylphosphatidylinositol (GPI) can control the sever-
ity of disease by neutralizing toxic components released
from ruptured infected erythrocytes [9,10].
The major merozoite surface protein -1 (MSP-1) was iden-
tified in immune complexes from merozoite lysates,
which provided the rationale for developing vaccines
against this antigen [11]. MSP-1 undergoes two successive
proteolytic cleavage events [12]. The second processing
event occurs immediately before invasion, resulting in the
cleavage of the p42 molecule into a p33 and a p19 frag-
ment. The p19 fragment remains attached to the mero-
zoite surface through a GPI anchor [13] and is comprised
of two epidermal growth factor (EGF)-like domains [14],
which may have a role in the invading complex. Serologi-
cal studies have provided significant evidence to suggest
that immune responses directed against the C-terminus of
MSP-1 (MSP-119 and MSP-142) are associated with immu-
nity in preclinical models [15-18], as well as from individ-
uals residing in endemic areas [16,19].
In the course of characterizing immune responses induced
by MSP-1 vaccines, it was recognized that: (1) proteins
produced by various expression systems differ in their
immunogenicity and ability to induce anti-parasite activi-
ties [20,21]; (2) not all MSP-1-based vaccines induce pro-
tective immunity [22] and; (3) the degree of inhibition
was dependent on the method chosen to measure inva-
sion- and growth inhibition mediated by anti-MSP-1p42
and that only the methods that are based on cell viability
and/or metabolic activity are able to accurately measure
growth inhibition, while all the methods tested were
equally able to detect invasion inhibition [23]. Thus,
selecting the appropriate method permits differentiation
between the various mechanisms by which antibodies
affect parasite development.
The current study was designed to investigate the effect of
anti-MSP-1p42 antibodies on intra-erythrocytic parasite
development and their consequences on parasite viability
and infectivity. Depending on the parasite clone, anti-
MSP-1p42 antibodies prevented schizont rupturing by
stalling or arresting intra-erythrocytic parasite develop-
ment likely through direct interactions with intra-erythro-
cytic parasites within the parasitophorous vacuole. The
nature of the inhibitory effect was strongly affected not
only by the parasite clone, but also by the fine-specificity
of the antibodies. Only antibodies that bound the p19
subunit, but not the EGF-like domain 1 or 2 subunits, dis-
played growth inhibitory activities indicating that protec-
tive epitopes are dependent on the tertiary structure of the
molecule.
Several important lessons can be gained from these find-
ings: (1) various allele-specific effector mechanisms can
develop to the same blood stage antigen; (2) while in vitro
assays provide a useful tool to determine vaccine efficacy,
such assays need to take into account the predominant
antibody-mediated effector mechanisms against a particu-
lar clone; (3) inhibitory anti-MSP-1 specific antibodies
map to epitopes formed through the "properly" folded
p19 subunit and not to its sub-domains [24,25]; (4) with
the exclusion of potential effector cells, only macromole-
cules of a defined size have access to the intra-erythrocytic
parasite either through the putative "parasitophorous
duct" or through the "leaky" erythrocytic membrane
[6,26], and thus MSP-1-specific antibodies could be used
as carriers and targeting moieties for anti-malarial drugs.
Methods
Parasite cultures
Complete media was prepared with RPMI 1640 (Invitro-
gen, Carlsbad, CA) containing 25 mM HEPES, 7.5% w/v
NaHCO3 and 10% human pooled serum (bloodtype O+).
Plasmodium falciparum clones 3D7, FVO and CAMP were
maintained and synchronized by the temperature cycling
method [27]. Unless stated otherwise, cultures in the pres-
ence or absence of immune serum were set up at approxi-
mately six hours before rupture occurred (starting
parasitaemia 0.3%, 1% haematocrit uninfected erythro-
cytes) in 96-well plates under static conditions.
Access of antibodies to the intra-erythrocytic parasite
To visualize the uptake of macromolecules, non-manipu-
lated 3D7 and FVO cultures (2–3% parasitaemia at 4%
haematocrit) were incubated at the late trophozoite/early
schizont stage with either 2 μl of 1:100 diluted yellow-
green fluorescent FluoSpheres beads (40 nm size, Molec-
ular Probes, Eugene, OR), or diluent (BlockAid, Molecular
Probes) or 1:50 diluted Alexa 488- (Molecular Probes) or
PE-conjugated antisera for two hours. Samples were
enriched for parasites by passing them through a column
(MS+) (Miltenyi Biotech, Auburn, CA) inserted into a
MiniMACS magnet (Miltenyi Biotech) at the end of the
incubation time to avoid any stress related artifacts due to
out-gassing.
Antigens
Escherichia coli-expressed recombinant MSP-1p42(3D7)
(FMP1, falciparum malaria protein 1), MSP-1p42(FVO)
(FMP003) and the codon harmonized MSP1p42(FVO)
(FMP010) were produced under GMP conditions as
described elsewhere [15,28,29].
Antibodies
New Zealand White rabbits (n = 8/immunization group,
Spring Valley Laboratories, Poolesville, MD) were immu-
nized subcutaneously four times with either recombinant
MSP-1p42 of the FVO clone (four immunizations with 36Malaria Journal 2009, 8:183 http://www.malariajournal.com/content/8/1/183
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μg) [15] or the 3D7 clone (prime with 225 μg and three
boosts with 50 μg each) [28] emulsified in complete/
incomplete Freund's adjuvant (CFA/IFA). Additional
experimental groups were: rabbits (n = 4) immunized
subcutaneously three times with 50 μg of codon harmo-
nized MSP-1p42(FVO) [29] in CFA/IFA and Montanide
ISA-720 (Seppic, Paris, France) and rabbits (n = 4) immu-
nized subcutaneously three times with 50 μg of reduced/
alkylated MSP-1p42 (3D7) and (FVO) in CFA/IFA (con-
trol sera) [23]. Serum pools were aliquoted and stored fro-
zen until analysis. Where indicated, immunoglobulins
were purified from sera obtained after immunization with
either reduced/alkylated MSP-1p42 (3D7 or FVO allele)
emulsified in CFA/IFA. Immunoglobulins were purified
using HiTrap Protein G columns (GE Healthcare, Piscata-
way, NJ) according to manufacturer's instructions and
conjugated with fluorochromes following the manufac-
turer's instructions. Fluorochromes used were Alexa 488
or phycoerythrin (both purchased from Molecular
Probes). Purified immunoglobulins were tested at con-
centrations normalized to the titers of the respective antis-
era. Both, antisera and purified immunoglobulins were
tested in growth inhibition assays using recombinant
MSP-1p42 antigen add-back (reversal of inhibition assay)
to assure that the activity seen was antigen-specific.
ELISA
ELISA assays were performed as previously described in
detail [30].
Affinity purification of MSP-1 subunit specific antibodies
GSH resin was coated with 2.5 mg/ml protein (GST-MSP-
1p19 and GST-p19 EGF-domain 1 or 2 of either the 3D7
or the FVO allele [15]). Pooled sera from five or eight rab-
bits, respectively, immunized with either MSP-
1p42(3D7)/FA or MSP-1p42(FVO)/FA were incubated
with protein-coated GSH resin (GE Healthcare) for 1 hr at
RT. Resin was washed and the bound antibodies were
eluted by washing the resin three times with 75 mM gly-
cine (pH = 3.0) and followed by two times with 0.5 M
NaCl. Eluted antibodies were analysed by SDS gel electro-
phoresis using 4–20% SDS-PAGE gels (Invitrogen,
Carlsbad, CA).
Microscopic analysis
Cultures were harvested at various time points as indi-
cated and blood smears were made from each well. Blood
smears were fixed in methanol and stained in a 10%
Giemsa solution (Sigma, St. Louis, MO) for 10 min. Slides
were washed in water and allowed to air dry before analy-
sis. Evaluation was performed at 1,000× magnification
(oil-immersion) using a Nikon E400 Eclipse microscope
and photographs were taken with an Olympus BX-50
microscope with digital camera (Magnafire Software).
Three slides per group were evaluated by counting 2000
erythrocytes (RBC) or 100 parasitized erythrocytes
(pRBCs)/slide in a blinded fashion.
Confocal microscopy
Confocal images were taken on a Nikon E800 microscope
and the laser confocal system, BioRad Radiance 2100.
Thirty layers at a spacing of 0.5 μm were scanned for each
image and then z-stacked (performing 3D Blind Deconvo-
lution on the stack (AutoDeblur deconvolution software,
AutoQuant Imaging Inc, Watervliet, NY)). Images were
analysed at 3% laser power.
Evaluation of invasion-/growth inhibition
Cultures for growth inhibition assays were set up at the
schizont stage and cultured for one cycle as described
[23]. For pLDH detection, cells were harvested, washed
and frozen at -30°C until analysis. pLDH was detected
and measured as described previously [31,32]. For flow
cytometric analysis of growth- and invasion inhibition, 50
μl culture aliquots were stained with hydroethidine (HE)
(Polysciences, Warrington, PA) or Syto-16 (Molecular
Probes, Eugene, OR). Stock solutions of HE were prepared
at 10 mg/ml dissolved in DMSO (Sigma) and stored at -
30°C. Samples were stained by adding 500 μl of freshly
diluted HE (diluted 1:200 in warm (37°C) phosphate
buffered saline (PBS) (Biowhittaker, Walkersville, MD))
to the parasite suspensions and incubating for 20 min at
37°C. Syto-16 was diluted to 200 nM with PBS; a 500 ml
aliquot was added to the parasite suspensions and incu-
bated for 30 min at 37°C. Staining was stopped by trans-
ferring the samples to ice (which allowed stabilization of
the staining for up to two hours) and diluted with 1 ml
PBS prior to analysis. The data were acquired on a FACS-
Calibur flow cytometer (Becton Dickinson, San Jose, CA)
using CellQuest software for acquisition and analysis.
Results
Immune rabbit sera raised against various MSP-1p42 
proteins are growth/invasion inhibitory against 
homologous and heterologous clones of P. falciparum
While some methods used to detect in vitro anti-parasitic
activities are able to measure invasion inhibition, only the
methods that require metabolically active cells such as
staining parasitized RBCs with hydroethidine (HE) or
detection of pLDH in cultures are able to measure growth
inhibition [23]. To determine whether immunizations
with MSP-1p42 always induce growth inhibitory antibod-
ies regardless of the adjuvant and the immunogen, rabbits
were immunized with various immunogen/adjuvant
combinations (Figure 1). The immunogens compared
were MSP-1p42 of the 3D7 allele [28] or FVO allele
(either the wild-type nucleotide sequence containing a
single codon substitution (mut7) (FMP003) [15] or the
full gene "codon harmonized" nucleotide sequence,
FMP010 [29] adjuvanted in either Freund's adjuvant (FA)Malaria Journal 2009, 8:183 http://www.malariajournal.com/content/8/1/183
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or Montanide ISA-720. Growth inhibition was evaluated
by flow cytometric analyses using Syto-16 DNA dye bind-
ing for total parasitaemia (regardless of viability of pRBC)
and by hydroethidine (HE) DNA dye binding (for viable
parasitaemia). Anti-MSP-1p42 specific antibodies inhib-
ited invasion (Syto-16) and growth (HE) on 3D7 parasites
(Figure 1A), while the various antisera tested mainly
inhibited invasion of FVO parasites (Figure 1B). Although
quantitative differences in the growth inhibitory activity
of the various sera were noted, no qualitative differences
between the immunogen/adjuvant combinations tested
were observed. As no qualitative differences were seen
between FMP003 or FMP010 vaccines (both of which are
based on MSP-1p42 of the FVO clone), only sera raised
using the FMP003 vaccine were used in subsequent exper-
iments. Interestingly, both FVO-based vaccines induced
antibodies with higher inhibitory activities against 3D7
parasites than the homologous FMP1 vaccine. This is not
necessarily reflected in the reactivity of the antibodies in
the ELISA-based analysis (Figure 1). The higher GIA activ-
ities or specificities against the heterologous strain may be
due to improved protein structures of the recombinant
FVO proteins thus more closely resembling the native
structure.
MSP-1p42 specific antibodies cause morphological 
changes to parasite in in vitro cultures
3D7, FVO and CAMP/FUP schizont stage parasites were
incubated with either control sera (MSP-1p42 reduced/
alkylated (R/A)) or MSP-1p42 of the 3D7 or FVO allele for
10–22 hrs (i.e., 6 and 12 hrs post invasion). Representa-
tive examples of the predominant morphologies are
shown in Figure 2, with quantitative evaluation in Table
1. 3D7 cultures incubated with anti-MSP-1p42 antisera
contained predominantly ring stage parasites and aggluti-
nated merozoites at six hours post-invasion (pI). Con-
versely, for the FVO and CAMP/FUP cultures at six hours
pI, newly invaded rings and agglutinated merozoites were
observed (Figure 2). Furthermore, stalled schizonts were
identifiable as mature schizonts with pronounced nuclei
which persist in culture several hours beyond the time
point when schizonts in control cultures have ruptured
and released merozoites. Stalled schizonts did not rupture
throughout the experiment and were only observed in the
Anti-MSP-1p42 specific sera act to inhibit either merozoite invasion or parasite growth, depending on the parasite clone Figure 1
Anti-MSP-1p42 specific sera act to inhibit either merozoite invasion or parasite growth, depending on the par-
asite clone. Responses of 3D7 (Panel A) and FVO (Panel B) parasites to various anti-MSP-1p42 antisera (at 20% v/v) were 
tested and evaluated by determining inhibitory activity of the sera based on total parasitaemia (Syto-16; black bars) and viable 
parasitaemia (HE, white bars). Test sera used: MSP-1p42 (FVO)(FMP003, FMP010) or MSP-1p42 (3D7) (FMP1) in Freund's 
adjuvant (FA) or FMP003 and FMP010 in Montanide ISA 720. Data are the mean and SEM of three independent experiments. 
The ELISA data are expressed as OD 1 titers against the MSP-1p42(3D7) (Panel A) or MSP-1p42 (FVO) (Panel B) plate antigen.
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presence of immune sera. Similar results were obtained
when using either purified immunoglobulins from
immunized rabbits or the serum from a malaria-exposed
individual, indicating that the observed effects were not
artifacts caused by either the control or immune rabbit
serum.
To test whether stalled schizonts had lost the ability to
rupture, the observation time was expanded from six
hours pI to the next invasion cycle (i.e., 40 hrs for 3D7, 46
hrs for FVO) (Figure 3). For these experiments, total para-
sitaemia was determined by evaluating Giemsa-stained
blood smears from parallel cultures. As previously noted
[23], this readout method only detects invasion inhibi-
tion and not growth inhibition in a single-cycle experi-
ment. This analysis demonstrated that the phenotype of
the "stalled schizont" was permanent as no spike in para-
sitaemia was observed in the next cycle. These stalled sch-
izonts started to either condense or disintegrate and were
not observed after more than 12 hrs pI.
Macromolecules and antibodies have access to the intra-
erythrocytic parasite
The observation that antibodies can mediate growth retar-
dation including the stalling of schizonts indicates that
antibodies can access intra-erythrocytic parasite. Previous
findings suggested that the membranes of infected-eryth-
rocytes become "leaky" prior to rupture [11], providing a
route through which antibodies could enter the infected
RBC. An alternative explanation is that the site of invasion
on the erythrocyte membrane never completely closes,
leaving a pore and a small duct extending into the parasi-
tophorous vacuole [26]. This parasitophorous duct is used
for transporting macromolecules into the parasitopho-
rous vacuole bypassing the erythrocyte membrane
[26,33].
To address the question of whether antibodies have access
to intra-erythrocytic parasites, parasite cultures were incu-
bated with either fluorochrome-labeled beads or fluoro-
chrome-labeled anti-MSP-1p42 antibodies for two hours
and then were evaluated by confocal microscopy (Figure
4). Fluorescein-labeled beads as well as the purified
labeled antibodies were detected within infected erythro-
cytes and in the case of the fluorescein-labeled beads, out-
lined a labyrinth-like structure around the intra-
erythrocytic parasites similar to the structures described by
Pouvelle et al. [33] (Figure 4A, left column). In the case of
the Alexa 488-labeled MSP-1p42 specific antibodies, a
grape-like staining pattern consistent with an MSP-1-like
staining [34] was observed in the pRBC (Figure 4A, mid-
dle and right column). No differences between the two
Table 1: Quantitative analysis of Giemsa-stained blood smears of cultures incubated with various antisera.
(A) 6 hrs post invasion
Test clone Antisera testeda Proportion of phenotype [%]b
rings schizonts agg mz
3D7 Control (R/A) 100 0 n
Anti-MSP-1p42(3D7) 100 0 y
Anti-MSP-1p42(FVO) 100 0 y
FVO Control (R/A) 98.8 1.2 n
Anti-MSP-1p42(3D7) 70.0 30.0 y
Anti-MSP-1p42(FVO) 65.4 34.6 y
CAMP/FUP Control (R/A) 97.1 2.9 n
Anti-MSP-1p42(3D7) 79.2 20.8 y
Anti-MSP-1p42(FVO) 74.3 25.7 y
(B) 12 hrs post invasion
Test clone Antisera testeda Proportion of phenotype [%]b
rings schizonts agg mz
3D7 Control (R/A) 100 0 n
Anti-MSP-1p42(3D7) 100 0 y
Anti-MSP-1p42(FVO) 100 0 y
FVO Control (R/A) 99.4 0.6 n
Anti-MSP-1p42(3D7) 73.4 26.6 y
Anti-MSP-1p42(FVO) 61.9 38.1 y
CAMP/FUP Control (R/A) 96.6 3.4 n
Anti-MSP-1p42(3D7) 75.2 24.8 y
Anti-MSP-1p42(FVO) 70.1 29.9 y
a Antisera were tested at 20% (v/v) serum concentration. The control group R/A consists of pooled sera from rabbits immunized with reduced/
alkylated MSP-1p42 in FA (see Materials and Methods).
b Analysis was done by counting sufficient fields to accumulate either 2,000 RBCs or 100 pRBC. The pRBC were classified and counted based on 
their phenotype. No attempts were made to count agglutinated merozoites (agg mz) and thus only their presence in the culture was noted as y, yes 
and n, no. Data shown in the table correspond to the data shown in Figure 2.Malaria Journal 2009, 8:183 http://www.malariajournal.com/content/8/1/183
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test clones, 3D7 and FVO, could be found with regards to
either staining intensity or staining pattern. Although
antibodies from both control- and immune sera were
present in the pRBCs, the staining pattern with the control
antibodies was only discernable at the highest setting for
sensitivity (95% laser power), were highly diffuse and did
not outline the parasites' nuclei similar to the immune
serum (Figure 4B). The micrographs for the immune anti-
bodies were taken at 3% laser power (at which the control
antibodies did not show any staining).
Anti-MSP-1p42 specific antibodies retard the development 
of intra-erythrocytic parasites
Evaluating blood smears from cultures treated with MSP-
1p42 specific antibodies taken at various time points
throughout the cycle revealed that growth retardation
became apparent mainly at the trophozoite stage for 3D7
parasites. The observed growth retardation was quantified
by staining for parasite DNA in RBCs cultured in the pres-
ence of either control sera or immune sera. Shown in Fig-
ure 5, 3D7 (Panel A) and FVO (Panel B) parasite cultures
taken at various times throughout the cycle were stained
with Syto-16. The MFI of control cultures was set as 1 and
any changes in MFI of the cultures treated with immune
sera was calculated (Figure 5A, B). Thus, for anti-MSP-
1p42-treated parasite cultures having lower DNA content
than control cultures the MFI would be < 1. Lower DNA
content for cultures treated with immune sera compared
to control cultures at 12 hrs pI were observed for both
3D7 and FVO parasites (30–40% less in 3D7 parasites and
approximately 25% reduction in FVO parasites). In addi-
tion, 3D7 parasites were consistently affected by the pres-
ence of the immune sera as there was a further reduction
in DNA content. This was confirmed by evaluating these
same cultures using HE, where a significant growth inhi-
bition of 3D7 parasites was measured compared to FVO
parasites starting at the early trophozoite stage [23]. FVO
parasites however, appeared to be influenced by MSP-
1p42 specific antibodies only at the early and the late
stages of the cycle, with growth inhibitory effects undetec-
table by HE [23].
MSP-1p42 and p19-specific antibodies are responsible for 
the functional activity in immune sera
MSP-1 specific antibodies were found to be associated
with reduced parasite density and clinical disease and are
mainly directed to the C-terminal-MSP-1p19 portion of
MSP-1 in seroepidemiological studies [16,35]. Determi-
Anti-MSP-1p42 antisera prevent the rupture of heterologous and homologous clones, FVO and CAMP/FUP, but not 3D7 Figure 2
Anti-MSP-1p42 antisera prevent the rupture of heterologous and homologous clones, FVO and CAMP/FUP, 
but not 3D7. Cultures were set up with schizont stage pRBCs in the presence of sera (at 20% v/v) from rabbits immunized 
with either MSP-1p42(3D7) (FMP1) or MSP-1p42(FVO) (FMP003) emulsified in FA. Sera from rabbits immunized with reduced/
alkylated MSP-1p42(R/A)/FA were used as the negative control. Triplicate blood smears were prepared from each culture 6 
hrs after invasion was completed. Micrographs of representative parasites were taken at 1000× magnification.Malaria Journal 2009, 8:183 http://www.malariajournal.com/content/8/1/183
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nation of antibody fine specificities either by using an
MSP-1p42 fragment specific ELISA from an Aotus monkey
study [15] or by sub-domain affinity purifications from
protective hyperimmune immunoglobulin [16] showed
that the antibodies directed to EGF-like domain 2 were
associated with parasitological readouts or growth inhibi-
tory activities, respectively, while antibodies directed to
the EGF-like domain 1 were associated primarily with
"blocking" activities, i.e., antibodies that interfere with the
activity of inhibitory antibodies [25]. To date, antibodies
directed primarily to either EGF-like domain 1 or domain
2 appear to have a less clear role. Thus, experiments were
designed to address whether inhibitory antibody activities
induced by vaccinating rabbits with MSP-1p42 mapped to
the whole MSP-1p42 molecule or to the subunits (MSP-
1p19, EGF-like domain 1 or EGF-like domain 2). Affinity-
purified antibodies from sera of rabbits immunized with
either MSP-1p42(3D7) or MSP-1p42(FVO) were gener-
ated using various subunit fragments: MSP-1p42, MSP-
1p19 and MSP-1p19 EGF domain 1 and domain 2 repre-
sentative of both the 3D7 or FVO allele [15,28]. The affin-
ity-purified subunit-specific antibodies were tested (after
normalizing to their starting concentration within the
serum) for their anti-parasite activity using flow cytometry
(Figure 6). The inhibitory effects of the respective antibod-
ies were evaluated by measuring total parasitaemia (Syto-
16 staining, indicative of invasion inhibition) and viable
parasitaemia (HE-staining, indicative of growth inhibi-
tion). These studies identified that: (1) MSP-1p42 specific
antibodies act through growth- and invasion inhibitory
activities. (2) Purified antibodies to MSP-1p19 act in an
allele-specific manner. For example, invasion, but not
growth of FVO parasites was inhibited, while growth, but
not invasion of 3D7 and CAMP/FUP was inhibited by
anti-MSP-1p19 antibodies. The highest level of growth
inhibition observed with these antibodies was against
3D7 followed by CAMP parasites. And conversely, MSP-
1p19 (FVO) purified antibodies act against FVO parasites
by both invasion and growth inhibition, but do not
inhibit either 3D7 or CAMP parasites by invasion inhibi-
tion (Figure 6, Left Panels A and C). Finally, (3) antibod-
ies specific for either EGF-like domain 1 or EGF-like
Anti-sera raised to MSP-1p42 treated parasite cultures results in retardation of parasite development Figure 3
Anti-sera raised to MSP-1p42 treated parasite cultures results in retardation of parasite development. 3D7 
(panel A) and FVO (panel B) schizonts were cultured in the presence of control serum or immune rabbit serum (at 20% v/v) 
raised against either reduced/alkylated MSP-1p42 (R/A, control serum) or MSP-1p42(3D7) (FMP1) or MSP-1p42(FVO) 
(FMP003) emulsified in FA. Parallel cultures were harvested at indicated time points after completed rupture and slides pre-
pared in triplicates per treatment group and time point. Micrographs of representative parasites in Giemsa-stained blood 
smears were taken at 1000× magnification.
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domain 2 for either allele had no anti-parasite activities
(data not shown).
Discussion
There is significant data in the literature supporting the
development of MSP-1p42 as a blood-stage vaccine candi-
date primarily as antibodies directed against this antigen
have been shown to protect against homologous chal-
lenge in Aotus monkey studies, albeit using strong adju-
vants like complete Freund's/incomplete Freund's [15], as
well as shown to correlate with reduced parasite burden
and clinical disease from human sero-epidemiological
studies (reviewed in [36]). Thus, it is crucial to understand
the potential mechanisms underlying the anti-parasitic
activities for this target antigen in order to design MSP-1-
based vaccines with maximal vaccine efficacy. In two
recent studies which compare various MSP-1-based vac-
cine candidates with regards to their immunogenicity and
ability to induce antibodies that mediate anti-parasitic
activity [20,21], the differences observed in antibody
binding and functional activities induced were attributed
to either the immunogens ability to induce more "biolog-
ically" relevant activities against the parasite or from the
effects on the immunogens conformation as a result of the
expression or purification systems utilized. This is not sur-
prising as the quality of the immune response induced
may be influenced by the quality of the protein produced.
To avoid issues of expression and purification process dif-
ferences, the recombinant MSP-1p42 molecules used as
immunogens in the current study were all expressed simi-
larly from E. coli and purified as soluble proteins
[15,28,29]. Where directly comparable, no apparent dif-
ferences were observed in the anti-parasitic activities
induced by either the single codon mutated MSP-1p42
(FMP003) and full gene codon harmonized MSP-1p42
(FMP010) in FA or Montanide ISA 720 as adjuvant. There-
fore, for at least the two adjuvants tested, the mode of
action of the functional activities induced in rabbits was
not adjuvant-dependent.
The present study demonstrates that antibodies directed
against MSP-1p42 play a complex role during invasion
and intra-erythrocytic maturation (growth) of parasites.
Using comparative studies of P. falciparum FVO, CAMP/
FUP and 3D7 parasite cultures, we made several observa-
tions: first, that the quality of the response of MSP-1p42
specific antibodies is independent of the immunogen and
adjuvant used (Figure 1); second, that the "type" of
response against the parasite, whether invasion or growth
inhibitory, was dependent on the assay clone, for
instance, invasion- and growth inhibition was observed
for 3D7 and CAMP/FUP parasites while only invasion
inhibition was observed for FVO parasites (Figures 1, 6);
third, that only antibodies raised against MSP-1p42 or
affinity-purified using either the 3D7 or FVO p19 frag-
ments had any inhibitory activity, while antibodies affin-
ity-purified using either the EGF-like domain 1 or 2 did
not (Figure 6); fourth, that the MSP-1p19 specific anti-
bodies component exhibited homologous allele-specific
inhibitory activities that were not observed for antibodies
to the total MSP-1p42; and finally, that antibodies were
able to enter viable infected erythrocytes and bind to
intra-erythrocytic parasites, and that likely through this
action, inhibit either further development or prevent rup-
ture of maturing schizonts (Figures 2, 5, 6).
The present study revealed various reaction patterns of
blood stage parasites in response to MSP-1p42 specific
antibodies: invasion inhibition mediated by preventing
schizont maturation ("stalled schizonts"), schizont rup-
turing and agglutination of merozoites prior to or upon
Fluorochrome labeled beads and anti-MSP-1p42 antibodies  enter viable pRBC and gain access to the intra-erythrocytic  parasites Figure 4
Fluorochrome labeled beads and anti-MSP-1p42 anti-
bodies enter viable pRBC and gain access to the 
intra-erythrocytic parasites. (A) 3D7 or FVO parasite 
cultures (2% hct, 2–3% parasitaemia) were incubated with 
either Fluorescein-labeled beads or 10% Alexa 488-conju-
gated anti-MSP-1p42 immunoglobulins (Igs). Igs were purified 
from rabbit sera after immunization with MSP-1p42(FVO) 
(FMP003) emulsified in FA. Igs were tested at the same titer 
as serum assay. (B) same as for panel A, except that pRBCs 
were incubated with either Alexa 488-labeled Igs derived 
from rabbits either immunized with reduced/alkylated MSP-
1p42 (negative control) or MSP-1p42(FVO) (FMP003) emul-
sified in FA. The confocal microscopy images were recorded 
at either 3% laser power (same power as the images in Panel 
A) or at 95% laser power (highest laser sensitivity). The 
center column shows the bright field image of the left col-
umn.
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their release (Figure 2). The observation that anti-MSP-
1p42 specific antibodies cannot prevent the rupture of
3D7 schizonts (Figure 2) is not due to a general inability
of the schizonts to be stalled as anti-AMA-1 specific anti-
bodies induced this phenotype as well (Bergmann-Leit-
ner, unpublished observations). Preventing schizonts
from rupturing permanently affected the schizonts, as no
spike in parasitaemia at any later time points could be
detected suggesting that the observed effect was likely not
due to a transient phenotype. Growth inhibition or retar-
dation becomes evident by progressive losses in the ability
to stain DNA with HE and reductions in the levels of
pLDH measured in the cultures in the presence of
immune serum. Moreover, growth retardation was
observed when pRBC cultures treated with either control
or immune serum were compared for their DNA content
as a measurement of parasite maturation (Figure 5). As
suggested by the HE-staining, 3D7 parasites were more
affected by the phenomenon of growth retardation than
were FVO parasites. However, measuring the DNA con-
tent as a marker for maturation does not necessarily indi-
cate that the effect of immune antibodies is persistent, i.e.,
even though the maturation is slowed these cultures
retained similar multiplication rates as control cultures.
Thus currently, the only feasible measures of growth inhi-
bition are those methods that are based on parasite viabil-
ity such as HE-staining of DNA and measurement of
pLDH [23].
In an effort to better understand how MSP-1p42 specific
antibodies affect intra-erythrocytic parasite development,
such that schizonts can no longer rupture, it was first cor-
roborated that antibodies, regardless of their specificity,
can enter infected RBCs (Figure 4), as shown previously
for other macromolecules, such as beads having diameters
up to 80 nm [26,33], iron chelators [37], antisense oligo-
nucleotides [38], plasmids [39] and antibodies [6]. In the
case where these antibodies are unable to prevent inva-
sion of erythrocytes, antibodies that are bound to para-
sites may be dragged into the newly invaded RBC and
remain bound to the ring stage parasite during the early
phases of development immediately after invasion
(unpublished observation, and [40]). A recent report
demonstrates that the p19 fragment of MSP-1 may be
involved in the formation of the food vacuole [41]. It
needs to be determined how antibody binding to p19 dur-
ing and after invasion affects the role of the molecule dur-
ing this crucial developmental step. In the later
development it is possible that the antibody-bound MSP-
1 on intra-erythrocytic parasites interferes with the ability
to cause the phenotypic changes on FVO and CAMP/FUP
schizonts that lead to rupture. Finally, this study
addressed the question of anti-MSP-1p42 specific anti-
bodies fine specificities and their role in mediating the
various phenotypes of invasion and growth inhibition
that were detected. To this end, antibodies were affinity-
purified using either recombinant MSP-1p19 or the EGF-
like domain 1 or 2 (representative of the 3D7 or FVO
allele) contained within the p19 fragment (Figure 6).
Flow cytometric analysis of parasite cultures treated with
the various antibody preparations derived from rabbit
immune serum revealed that only antibodies raised
against the MSP-1p42 or affinity purified antibodies spe-
cific for MSP-1p19 had any inhibitory activity. These
results are consistent with the findings obtained from nat-
urally-exposed Western Kenyan adults' immune sera
where using transgenic P. falciparum expressing MSP-1-
p19 orthologs, the majority of the inhibitory activity was
directed to the MSP-1p19 portion of the molecule
[19,35]. Affinity purified anti-MSP-1 antibodies using
EGF-like domain 1 and 2 proteins did not capture anti-
bodies that had any inhibitory function indicating that
Flow cytometric analysis reveals reduction in parasitaemia  for both 3D7 and FVO parasite cultures when MSP-1p42  specific antibodies are present Figure 5
Flow cytometric analysis reveals reduction in parasi-
taemia for both 3D7 and FVO parasite cultures when 
MSP-1p42 specific antibodies are present. Panel A, B: 
Changes in DNA content of RBC infected with either 3D7 
parasites (Panel A) or FVO parasites (Panel B) cultured 
either in the presence of anti-MSP-1p42(3D7) (FMP1) (closed 
circle) or anti-MSP-1p42(FVO) (FMP003) (open circle) 
(serum concentration = 20% v/v). Infected RBC were stained 
with Syto-16 and their DNA content determined by flow 
cytometry and compared to pRBC cultured in the presence 
of control sera (DNA content = 1). Panel C, D: representa-
tive histograms of 3D7 (Panel C) or FVO (Panel D) schizonts 
after culture with either control sera (black bold line, white 
area) or MSP-1p42(FVO) (FMP003) (thin line, grey area) spe-
cific antisera. Histogram analysis was used to derive the data 
shown in Panel A, B. Adjuvant used for all three groups was 
CFA/IFA. One of three representative experiments is shown.
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the crucial epitopes are formed by both domains or that
the epitope is larger than just one of the domains alone.
This finding is in agreement with epitope mapping studies
for the growth inhibitory mAb, namely 12.10 [42], where
both domains were required for mAb binding [25,43].
Interestingly, MSP-1p19-purified antibodies appeared to
be more allele-specific with regard to invasion inhibition
than the total MSP-1p42 antibody population as MSP-
1p19 (3D7) antibodies were only able to inhibit 3D7 par-
asites and to a lesser extent CAMP/FUP parasites and not
FVO parasites. Similarly, MSP-1p19 (FVO)-purified anti-
bodies only inhibited invasion of FVO parasites, while the
effect on 3D7 and CAMP/FUP parasites was solely
growth-inhibitory. Thus the mechanism of invasion inhi-
bition may be more allele-specific than the mechanism of
growth inhibition.
Conclusion
The findings from pre-clinical studies in rabbits provide
new insights into the possible mode of action of anti-
MSP-1p42 specific antibodies and their broader effect on
intra-erythrocytic stage parasite development and thus
solicit similar characterizations of antibodies directed
against other blood stage antigens. Likewise, affinity puri-
fication of MSP-1p42 specific antibodies isolated from
"protected" individuals residing in endemic regions may
further support and define the relevance of these findings
and lead to a better understanding of the role and modes
of action of these antibody activities.
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p19 of MSP-1p42 are responsible for inhibitory activ-
ity in immune serum. Antibodies from sera raised against 
MSP-1p42 of the 3D7 (FMP1) or FVO (FMP003) allele were 
purified using recombinant GST-MSP-1p19 either to 3D7 or 
the FVO allele and then tested for their functional activity. 
Cultures were set up at schizont stage in the presence of 
indicated antibody fractions (tested at the same titers as for 
the respective serum assays) and then incubated for 40 hrs. 
Invasion inhibition was measured by Syto-16 staining; growth/
invasion inhibition was measured by HE-staining and subse-
quent flow cytometry against 3D7 (Panel A), FVO (Panel B) 
and CAMP/FUP (Panel C) parasites. Data are expressed as 
mean percentage of inhibition from three separate experi-
ments (SEM). Asterisk indicates statistical difference of p < 
0.01 (Student's T-test) between Syto-16 and HE.
A
-20
0
20
40
60
80
B
%
 
P
a
r
a
s
i
t
e
 
I
n
h
i
b
i
t
i
o
n
-20
0
20
40
60
80
C
Specificity of Polyclonal Antibodies
 MSP1p42 (FVO) MSP1p19 (FVO) MSP1p42 (3D7) MSP1p19 (3D7)
-20
0
20
40
60
80
Hydroethidine
Syto-16
* *
* *Malaria Journal 2009, 8:183 http://www.malariajournal.com/content/8/1/183
Page 11 of 12
(page number not for citation purposes)
00006, Award Number AAG-P-00-98-00005, and by the United States 
Army Medical Research and Materiel Command.
References
1. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisid-
dhi T, Druilhe P: Antibodies that protect humans against Plas-
modium falciparum blood stages do not on their own inhibit
parasite growth and invasion in vitro, but act in cooperation
with monocytes.  J Exp Med 1990, 172:1633-1641.
2. Butcher GA, Cohen S, Garnham PC: Passive immunity in Plasmo-
dium knowlesi malaria.  Trans R Soc Trop Med Hyg 1970,
64:850-856.
3. Cohen S, Mc GI, Carrington S: Gamma-globulin and acquired
immunity to human malaria.  Nature 1961, 192:733-737.
4. Groux H, Gysin J: Opsonization as an effector mechanism in
human protection against asexual blood stages of Plasmo-
dium falciparum: functional role of IgG subclasses.  Res Immunol
1990, 141:529-542.
5. Perkins M: Approaches to study merozoite invasion of eryth-
rocytes.  Res Immunol 1991, 141:662-665.
6. Ahlborg N, Igbal J, Bjork L, Stahl S, Perlmann P, Berzins K: Plasmo-
dium falciparum: differential parasite growth inhibition medi-
ated by antibodies to the antigens Pf332 and Pf155/RESA.
Exp Parasitol 1996, 82:155-163.
7. Siddique AB, Ahlborg N, Wahlin Flyg B, Perlmann P, Berzins K: Anti-
bodies to sequences in a non-repeat region of Plasmodium
falciparum antigen Pf155/RESA inhibit either cytoadherence
or parasite growth in vitro.  Parasitology 1998, 117:209-216.
8. Siddique AB, Igbal J, Ahlborg N, Wahlin Flyg B, Perlmann P, Berzins K:
Antibodies to nonrepeat sequences of antigen Pf155/RESA
of Plasmodium falciparum inhibit parasite growth in vitro.  Par-
asitol Res 1998, 84:485-491.
9. Naik RS, Branch OH, Woods AS, Vijaykumar M, Perkins DJ, Nahlen
BL, Lal AA, Cotter RJ, Costello CE, Ockenhouse CF, et al.: Glycosyl-
phosphatidylinositol anchors of Plasmodium falciparum:
molecular characterization and naturally elicited antibody
response that may provide immunity to malaria pathogene-
sis.  J Exp Med 2000, 192:1563-1576.
10. Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH: Syn-
thetic GPI as a candidate anti-toxic vaccine in a model of
malaria.  Nature 2002, 418:785-789.
11. Lyon JA, Carter JM, Thomas AW, Chulay JD: Merozoite surface
protein-1 epitopes recognized by antibodies that inhibit Plas-
modium falciparum merozoite dispersal.  Mol Biochem Parasitol
1997, 90:223-234.
12. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA: Antibodies
inhibit the protease-mediated processing of a malaria mero-
zoite surface protein.  J Exp Med 1994, 180:389-393.
13. Gerold P, Schofield L, Blackman MJ, Holder AA, Schwartz RT: Struc-
tural analysis of the glycosyl-phosphatidylinositol membrane
anchor of the merozoite surface proteins-1 and -2 of Plasmo-
dium falciparum.  Mol Biochem Parasitol 1996, 75:131-143.
14. Morgan WD, Birdsall B, Frenkiel TA, Gradwell MG, Burghaus P, Syed
SE, Uthaipibull C, Holder AA, Feeney J: Solution structure of an
EGF module pair from the Plasmodium falciparum merozoite
surface protein 1.  J Mol Biol 1999, 289:113-122.
15. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS,
Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, et al.: The clin-
ical-grade 42-kilodalton fragment of merozoite surface pro-
tein 1 of Plasmodium falciparum strain FVO expressed in
Escherichia coli protects Aotus nancymai against challenge
with homologous erythrocytic-stage parasites.  Infect Immun
2005, 73:287-297.
16. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM: Human anti-
bodies to the 19 kDa C-terminal fragment of Plasmodium fal-
ciparum merozoite surface protein 1 inhibit parasite growth
in vitro.  Parasite Immunol 1999, 21:133-139.
17. Long CA, Daly TM, Kima P, Srivastava I: Immunity to erythrocytes
stages of malarial parasites.  Am J Trop Med Hyg 1994, 50:27-32.
18. Parkkinen J, Rahola A, von Bonsdorff L, Tolo H, Torma E: A modi-
fied caprylic acid method for manufacturing immunoglobu-
lin G from human plasma with high yield and efficient virus
clearance.  Vox Sang 2006, 90:97-104.
19. John CC, O'Donnell RA, Sumba PO, Moormann AM, Koning-Ward
TF, King CL, Kazura JW, Crabb BS: Evidence that invasion-inhib-
itory antibodies specific for the 19-kDa fragment of the
merozoite surface protein-1 (MSP-119) can play a protective
role against Blood-stage Plasmodium falciparum infection in
individuals in a malaria endemic area of Africa.  J Immunol
2004, 173:666-672.
20. Arnot DE, Cavanagh DR, Remarque EJ, Creasey AM, Sowa MP, Mor-
gan WD, Holder AA, Longacre S, Thomas AW: Comparative test-
ing of six antigen-based malaria vaccine candidates directed
toward merozoite-stage Plasmodium falciparum.  Clin Vaccine
Immunol 2008, 15:1345-1355.
21. Reed ZH, Kieny MP, Engers H, Friede M, Chang S, Longacre S, Mal-
hotra P, Pan W, Long C: Comparison of immunogenicity of five
MSP1-based malaria vaccine candidate antigens in rabbits.
Vaccine 2009, 27:1651-1660.
22. Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O,
Kaslow DC, Robinson R, Long CA, Miller LH: Efficacy of two alter-
nate vaccines based on Plasmodium falciparum merozoite
surface protein 1 in an Aotus challenge trial.  Infect Immun
2001, 69:1536-1546.
23. Bergmann-Leitner ES, Duncan EH, Mullen GE, Burge JR, Khan F, Long
CA, Angov E, Lyon JA: Critical evaluation of different methods
for measuring the functional activity of antibodies against
malaria blood stage antigens.  Am J Trop Med Hyg 2006,
75:437-442.
24. McBride JS, Heidrich HG: Fragments of the polymorphic Mr
185,000 glycoprotein from the surface of isolated Plasmo-
dium falciparum merozoites form an antigenic complex.  Mol
Biochem Parasitol 1987, 23:71-84.
25. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA,
Angov E, Ling IT, Fegeding K, Morgan WD, Ockenhouse C, et al.:
Inhibitory and blocking monoclonal antibody epitopes on
merozoite surface protein 1 of the malaria parasite Plasmo-
dium falciparum.  J Mol Biol 2001, 307:1381-1394.
26. Goodyer ID, Pouvelle B, Schneider TG, Trelka DP, Taraschi TF:
Characterization of macromolecular transport pathways in
malaria-infected erythrocytes.  Mol Biochem Parasitol 1997,
87:13-28.
27. Haynes JD, Moch JK: Automated synchronization of Plasmo-
dium falciparum parasites by culture in a temperature-
cycling incubator.  Methods Mol Med 2002, 72:489-497.
28. Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse
CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, et al.:
Development and pre-clinical analysis of a Plasmodium falci-
parum Merozoite Surface Protein-1(42) malaria vaccine.  Mol
Biochem Parasitol 2003, 128:195-204.
29. Angov E, Hillier CJ, Kincaid RL, Lyon JA: Heterologous protein
expression is enhanced by harmonizing the codon usage fre-
quencies of the target gene with those of the expression
host.  PLoS ONE 2008, 3:e2189.
30. Bergmann-Leitner ES, Mease RM, Duncan EH, Khan F, Waitumbi J,
Angov E: Evaluation of immunoglobullin purification methods
and their impact on quality and yield of antigen-specific anti-
bodies.  Mal J 2008, 7:129.
31. Basco LK, Marquet F, Makler MM, Le Bras J: Plasmodium falciparum
and Plasmodium vivax: lactate dehydrogenase activity and its
application for in vitro drug susceptibility assay.  Exp Parasitol
1995, 80:260-271.
32. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA,
Miller LH, Stowers AW: In vitro studies with recombinant Plas-
modium falciparum apical membrane antigen 1 (AMA1): pro-
duction and activity of an AMA1 vaccine and generation of a
multiallelic response.  Infect Immun 2002, 70:6948-6960.
33. Pouvelle B, Spiegel R, Hsiao L, Howard RJ, Morris RL, Thomas AP,
Taraschi TF: Direct access to serum macromolecules by
intraerythrocytic malaria parasites.  Nature 1991, 353:73-75.
34. Gilson PR, O'Donnell RA, Nebl T, Sanders PR, Wickham ME, McEl-
wain TF, de Koning-Ward TF, Crabb BS: MSP119 miniproteins can
serve as targets for invasion inhibitory antibodies in Plasmo-
dium falciparum provided they contain the correct domains
for cell surface trafficking.  Mol Microbiol 2008, 68:124-138.
35. O'Donnell RA, Koning-Ward TF, Burt RA, Bockarie M, Reeder JC,
Cowman AF, Crabb BS: Antibodies against Merozoite Surface
Protein (MSP)-119 are the major component of the invasion-
inhibitory response in individuals immune to malaria.  J
ExpMed 2001, 193:1403-1412.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2009, 8:183 http://www.malariajournal.com/content/8/1/183
Page 12 of 12
(page number not for citation purposes)
36. Mahanty S, Saul A, Miller LH: Progress in the development of
recombinant and synthetic blood-stage vaccines.  J Exp Biol
2003, 206:3781-3788.
37. Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZI:
The antimalarial action of desferal involves a direct access
route to erythrocytic (Plasmodium falciparum) parasites.  J
Clin Invest 1993, 91:218-224.
38. Dawson PA, Cochran DA, Emmerson BT, Gordon RB: Inhibition of
Plasmodium falciparum hypoxanthine-guanine phosphoribo-
syltransferase mRNA by antisense oligondeoxynucleotide
sequence.  Mol Biochem Parasitol 1993, 60:153-156.
39. Wu Y, Sifri CD, Lei HH, Su XZ, Wellems TE: Transfection of Plas-
modium falciparum within human red blood cells.  Proc Natl
Acad Sci USA 1995, 92:973-977.
40. Blackman MJ: Purification of Plasmodium falciparum mero-
zoites for analysis of the processing of merozoite surface
protein-1.  Methods Cell Biol 1994, 45:213-220.
41. Dluzewski AR, Ling IT, Hopkins JM, Grainger M, Margos G, Mitchell
GH, Holder AA, Bannister LH: Formation of the food vacuole in
Plasmodium falciparum: a potential role for the 19 kDa frag-
ment of merozoite surface protein 1 (MSP1(19)).  PloS ONE
2008, 29:e2085.
42. Cavanagh DR, McBride JS: Antigenicity of recombinant proteins
derived from Plasmodium falciparum merozoite surface pro-
tein 1.  Mol Biochem Parasitol 1997, 85:197-211.
43. Autore F, Melchiorre S, Kleinjung J, Morgan WD, Fraternali F: Inter-
action of malaria parasite-inhibitory antibodies with the
merozoite surface protein MSP1–19 by computational dock-
ing.  Proteins 2007, 66:513-527.